CHENGDU, China, Nov. 27, 2025 /PRNewswire/ -- On November 25, 2025, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC)...
Hence then, the article about the annals of oncology publishes results of phase ii study of sacituzumab tirumotecan monotherapy for urothelial carcinoma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma )
Also on site :
- Tornado warning issued, and quickly cancelled, over Alhambra
- Governor Hochul: Annual statewide donation drive is complete
- Skier dies in collision with tree at Colorado’s Aspen Mountain, resort officials confirm